About CFXCapital
Who Is CFXCapital?
CFXCapital is a US-registered investment platform operating under the domain cfxip.us. According to official records, the company was founded on October 21, 2025, and is registered at 304 North Cardinal St., Dorchester Center, MA 02124. The firm does not hold any regulatory licences from financial authorities, which is a significant factor for traders to consider.
Despite being based in the United States, CFXCapital is not registered with the Commodity Futures Trading Commission (CFTC) or the Securities and Exchange Commission (SEC), meaning it operates outside the typical regulatory framework for US investment firms. This absence of oversight places the burden of due diligence firmly on the client.
Account Types and Minimum Deposits
CFXCapital offers a multi-tier account structure with seven distinct levels, ranging from the BEGINNER account with a $300 minimum deposit to the PREMIUM account requiring $10,000. The account names—BEGINNER, ENTREPRENEUR, BOOST, DIAMOND, SILVER, GOLD, and PREMIUM—suggest a hierarchy designed to cater to different investor budgets.
Notably, the broker does not disclose maximum leverage or specific trading conditions for any of these accounts in publicly available information. This lack of transparency makes it difficult for potential clients to evaluate the cost and risk of trading with the firm.
Product Offering and Instruments
Based on the official website, CFXCapital appears to focus on binary options and cryptocurrency portfolio investments. The site promotes a 'binary option marketplace' and claims to offer 'the most cutting-edge' platform for this product type. However, no detailed instrument list (such as forex pairs, indices, or commodities) is provided.
Given the emphasis on binary options, the broker likely does not offer traditional forex or CFD trading. Binary options are high-risk instruments that are banned or heavily restricted in many jurisdictions, including the EU and UK, due to their speculative nature.
Regulatory Status and Risk Considerations
As per FXCanary's records, CFXCapital has no registered regulators. This means no external body monitors the firm's financial practices, client fund segregation, or dispute resolution procedures. The FXCanary Scam Risk Score of 57/100 (Elevated) reflects this lack of oversight and the general opacity of the broker's operations.
Traders should be aware that unregulated brokers carry inherent risks, including potential difficulties in withdrawing funds, lack of recourse in case of disputes, and the possibility of sudden closure. The elevated risk score indicates that caution is warranted.
Geographic Reach and Target Audience
While the broker is registered in the United States, its website does not explicitly state which countries it accepts clients from. Given the US regulatory environment, it is unlikely that CFXCapital can legally solicit US residents without proper registration. The target audience may therefore be international investors seeking binary options or crypto investment opportunities.
The high minimum deposit for premium accounts ($10,000) suggests the firm may be targeting affluent individuals, while the lower tiers ($300) aim to attract smaller retail investors. However, without clear regulatory protections, any investor considering CFXCapital should proceed with extreme caution.
Transparency and Customer Support
Publicly available information about CFXCapital is limited. The website provides minimal details about company leadership, track record, or client feedback—no independent user reviews were found at the time of writing. This lack of transparency is a common red flag among lesser-known brokers.
Potential clients are advised to conduct thorough due diligence, including verifying any claims made on the website through independent sources. The absence of a physical office address beyond a PO-box-style location and the lack of verifiable regulatory credentials further underscore the need for caution.
Overview compiled by FXCanary from regulatory records and public data. full CFXCapital review